Quarterly report (Form 10-Q)
Bristol Myers Squibb 10-Q for Quarter ended Sep 30, 2026
Filing excerpt
FDA approval of Zenbexus (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for the treatment of adult patients with MM who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.